# SLC2A4RG

## Overview
SLC2A4RG, or solute carrier family 2 member 4 regulator, is a gene that encodes the SLC2A4 regulator protein, which functions primarily as a transcription factor. This protein is involved in the regulation of glucose transporter type 4 (GLUT4) and plays a significant role in cellular glucose homeostasis. The SLC2A4 regulator protein is characterized by its ability to bind specific DNA sequences, thereby influencing the expression of genes involved in apoptotic pathways, such as caspase-3 and caspase-6. It is particularly noted for its tumor-suppressive activities in glioma cells, where its nuclear localization is crucial for inducing apoptosis. The interaction of SLC2A4RG with the protein 14-3-3θ modulates its subcellular localization and function, impacting its role in cancer progression (Yun2019Shuttling). Mutations and expression alterations of SLC2A4RG have been implicated in various cancers, including glioma and metastatic breast cancer, highlighting its potential as a therapeutic target and prognostic marker (Paul2020Genomic; Yun2019Shuttling).

## Clinical Significance
Mutations and alterations in the expression of the SLC2A4RG gene have been implicated in various diseases, particularly glioma and metastatic breast cancer. In glioma, SLC2A4RG acts as a tumor suppressor, with its expression significantly downregulated in high-grade gliomas compared to low-grade gliomas and normal brain tissues. This downregulation is associated with increased tumor growth and poorer patient prognosis, as low nuclear expression of SLC2A4RG correlates with shorter overall survival in glioma patients (Yun2019Shuttling). The gene's nuclear localization is crucial for its tumor-suppressive function, and its interaction with the protein 14-3-3θ, which sequesters SLC2A4RG in the cytoplasm, is linked to decreased apoptosis and increased tumor progression (Yun2019Shuttling).

In metastatic breast cancer, SLC2A4RG is identified as a significantly mutated gene, with mutations co-occurring with copy number gains. These alterations are more frequent in metastases than in primary tumors, suggesting a role in treatment resistance and metastatic progression (Paul2020Genomic). The gene's involvement in these cancers highlights its potential as a therapeutic target and prognostic marker.

## Interactions
SLC2A4RG interacts with the protein 14-3-3θ, which plays a significant role in modulating its function in glioma cells. This interaction affects the subcellular localization of SLC2A4RG, promoting its retention in the cytoplasm and reducing its presence in the nucleus. The cytoplasmic sequestration of SLC2A4RG by 14-3-3θ is associated with a decrease in its tumor-suppressive activities, as nuclear localization is crucial for its role in inducing apoptosis through the transactivation of caspase-3 and caspase-6 genes (Yun2019Shuttling).

The interaction between SLC2A4RG and 14-3-3θ was confirmed through co-immunoprecipitation and GST pull-down assays, highlighting the importance of this interaction in glioma pathology. The presence of 14-3-3θ correlates with higher pathological grades of glioma and shorter overall survival in patients, suggesting that it negatively regulates the apoptotic function of SLC2A4RG by altering its localization and interaction with apoptotic pathways (Yun2019Shuttling).

SLC2A4RG also acts as a transcription factor, binding to a specific 7-bp consensus sequence (GCCGGCG) in the promoter regions of target genes, including caspase-3 and caspase-6, to regulate their expression and promote apoptosis in glioma cells (Yun2019Shuttling).


## References


[1. (Paul2020Genomic) Matt R. Paul, Tien-chi Pan, Dhruv K. Pant, Natalie N.C. Shih, Yan Chen, Kyra L. Harvey, Aaron Solomon, David Lieberman, Jennifer J.D. Morrissette, Danielle Soucier-Ernst, Noah G. Goodman, S. William Stavropoulos, Kara N. Maxwell, Candace Clark, George K. Belka, Michael Feldman, Angela DeMichele, and Lewis A. Chodosh. Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. Journal of Clinical Investigation, July 2020. URL: http://dx.doi.org/10.1172/jci129941, doi:10.1172/jci129941. This article has 23 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci129941)

[2. (Yun2019Shuttling) Dapeng Yun, Hongxiang Wang, Yuqi Wang, Yuanyuan Chen, Zhipeng Zhao, Jiawei Ma, Yuanyuan Ji, Qilin Huang, Juxiang Chen, Hongyan Chen, and Daru Lu. Shuttling slc2a4rg is regulated by 14-3-3θ to modulate cell survival via caspase-3 and caspase-6 in human glioma. EBioMedicine, 40:163–175, February 2019. URL: http://dx.doi.org/10.1016/j.ebiom.2019.01.030, doi:10.1016/j.ebiom.2019.01.030. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ebiom.2019.01.030)